BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - BioNTech ( NASDAQ:BNTX )
Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. Data from Summit Therapeutics Inc.
| Ticker |
Sentiment |
Impact |
|
AKESF
|
Neutral
|
11 %
|
|
GS
|
Somewhat Bullish
|
21 %
|
|
BNTX
|
Bullish
|
58 %
|
|
SMMT
|
Somewhat Bullish
|
21 %
|
